AI In Vitro Diagnostics Market Outlook 2025-2030: Growth Trends By Test Types, Applications, Technologies, End Users, Components, Deployment Modes And Regions

(MENAFN- GlobeNewsWire - Nasdaq) AI is revolutionizing the IVD market by enhancing diagnostic accuracy and speed. Key opportunities lie in AI integration across workflows, cloud solutions, regulatory support, and supply chain strategies. Focusing on transparency, interoperability, and resilience will propel stakeholder success in this dynamic landscape.

Dublin, Oct. 03, 2025 (GLOBE NEWSWIRE) -- The "AI In Vitro Diagnostic Market - Global Forecast 2025-2030" report has been added to ResearchAndMarkets's offering.

Artificial intelligence is redefining the in vitro diagnostics (IVD) market, enabling organizations to drive operational efficiency, accuracy, and adaptability amid ongoing industry changes. Leadership teams navigating this dynamic landscape require actionable insight to optimize resource allocation, ensure compliance, and position their businesses for sustained competitive advantage.

Market Snapshot: AI-Enabled In Vitro Diagnostics

The AI-powered in vitro diagnostics market is experiencing significant growth, shaped by advancements in machine learning, deep learning, computer vision, and natural language processing. Demand for high-throughput laboratory workflows and precision-driven clinical results is compelling diagnostic developers and healthcare providers alike to integrate intelligent automation across the value chain.

Growing adoption of cloud-native solutions and evolving regulatory pathways further facilitate the rapid implementation of next-generation diagnostic systems. As the convergence of digital pathology, genomics, and bioinformatics accelerates, stakeholders are seeking to realign strategies, with a strong focus on algorithmic transparency, robust validation, and efficient deployment models.

Scope & Segmentation of the AI In Vitro Diagnostics Market

• Test Types: Flow cytometry, immunoassay, microarray, next generation sequencing (exome sequencing, targeted panel, transcriptome sequencing, whole genome sequencing), PCR.
• Applications: Autoimmune, cardiology, genetic testing, infectious disease (bacterial infection, parasitic infection, viral infection), oncology.
• Technologies: Computer vision, deep learning, machine learning (reinforcement learning, supervised learning, unsupervised learning), natural language processing.
• End Users: Diagnostic laboratories, hospitals and clinics, pharmaceutical companies, research institutes.
• Components: Hardware, services (consulting, integration, support), software.
• Deployment Modes: Cloud based, hybrid, on premise.
• Key Regions: Americas (United States-California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).

Key Takeaways for Senior Decision-Makers

• AI is transforming diagnostic workflows, moving from manual interpretation techniques to data-driven models that enhance clinical confidence and speed up time-to-result cycles.
• Integration of digital pathology and comprehensive bioinformatics requires organizations to re-evaluate their technology stacks and ensure modular, interoperable infrastructure for future-proof flexibility.
• Regulatory agencies are updating frameworks to support AI-based diagnostic approvals, prioritizing transparent validation processes and robust performance standards.
• Regional market dynamics, including private investment climates and regulatory harmonization efforts, influence adoption rates and go-to-market requirements across different geographies.
• Enhanced supply chain resiliency, through nearshoring and domestic manufacturing partnerships, is becoming critical in response to international trade disruptions and tariff implementations.
• Successful market players use both in-house innovation and targeted acquisitions, while building cross-sector partnerships to maximize data orchestration and clinical integration capabilities.

Tariff Impact on the U.S. Value Chain

The 2025 tariffs are affecting the United States IVD market by increasing import duties on critical components such as specialized reagents, microfluidic devices, and semiconductor chips for AI accelerators. Diagnostic companies are responding by strengthening ties with domestic contract manufacturers, expanding in-house reagent production, and exploring vertical integration to offset cost pressures and ensure supply chain stability.

Methodology & Data Sources

This research utilizes a comprehensive methodology, combining rigorous secondary analysis of peer-reviewed publications, regulatory releases, clinical trial registries, and patent filings. Primary interviews with laboratory directors, software developers, and regulatory experts supplement the data, while proprietary analytics and triangulation ensure well-grounded segmentation and actionable findings.

Why This Report Matters

• Delivers segmented insights on test types, applications, technologies, and regional opportunities for strategic planning.
• Identifies regulatory and operational factors influencing successful AI integration for IVD developers, investors, and healthcare leaders.
• Supports decision-makers in mitigating risks and capitalizing on evolving tariff and supply chain scenarios.

Key Topics Covered
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Regulatory evolution for AI driven in vitro diagnostic devices under emerging global standards
5.2. Integration of multiomic data and machine learning algorithms in in vitro diagnostic assay development
5.3. Adoption of edge computing and embedded AI for rapid point of care in vitro diagnostic testing
5.4. Implementation of explainable AI models to enhance clinical trust in in vitro diagnostic workflows
5.5. Strategic partnerships between AI startups and established in vitro diagnostic manufacturers for scalability
5.6. Data governance and privacy frameworks for protecting patient information in AI driven diagnostic pipelines
5.7. Utilization of digital pathology imaging combined with AI for improved biomarker detection accuracy
6. Market Insights
6.1. Porter's Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. AI In Vitro Diagnostic Market, by Test Type
8.1. Introduction
8.2. Flow Cytometry
8.3. Immunoassay
8.4. Microarray
8.5. Next Generation Sequencing
8.5.1. Exome Sequencing
8.5.2. Targeted Panel
8.5.3. Transcriptome Sequencing
8.5.4. Whole Genome Sequencing
8.6. PCR
9. AI In Vitro Diagnostic Market, by Application
9.1. Introduction
9.2. Autoimmune
9.3. Cardiology
9.4. Genetic Testing
9.5. Infectious Disease
9.5.1. Bacterial Infection
9.5.2. Parasitic Infection
9.5.3. Viral Infection
9.6. Oncology
10. AI In Vitro Diagnostic Market, by Technology
10.1. Introduction
10.2. Computer Vision
10.3. Deep Learning
10.4. Machine Learning
10.4.1. Reinforcement Learning
10.4.2. Supervised Learning
10.4.3. Unsupervised Learning
10.5. Natural Language Processing
11. AI In Vitro Diagnostic Market, by End User
11.1. Introduction
11.2. Diagnostic Laboratories
11.3. Hospitals And Clinics
11.4. Pharmaceutical Companies
11.5. Research Institutes
12. AI In Vitro Diagnostic Market, by Component
12.1. Introduction
12.2. Hardware
12.3. Services
12.3.1. Consulting
12.3.2. Integration
12.3.3. Support
12.4. Software
13. AI In Vitro Diagnostic Market, by Deployment Mode
13.1. Introduction
13.2. Cloud Based
13.3. Hybrid
13.4. On Premise
14. Americas AI In Vitro Diagnostic Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa AI In Vitro Diagnostic Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific AI In Vitro Diagnostic Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
The companies profiled in this AI In Vitro Diagnostic Market report include:

• F. Hoffmann-La Roche AG
• Abbott Laboratories
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• bioMerieux SA
• Sysmex Corporation
• QIAGEN N.V.
• Ortho Clinical Diagnostics, Inc.
• Hologic, Inc.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN03102025004107003653ID1110147288